December 1st, 2014
Selections from Richard Lehman’s Literature Review: December 1st
Richard Lehman, BM, BCh, MRCGP
This week’s topics include atenolol vs. losartan in children and young adults with Marfan’s syndrome, the Japanese Primary Prevention Project, and more.
November 18th, 2014
Losartan No Better Than Atenolol in Marfan’s Syndrome
Larry Husten, PHD
Beta-blockers have been the standard treatment for people with Marfan’s syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people. The goal of treatment is to prevent or slow down the dilation of the aorta and avoid aortic dissection, the main cause of death. In recent years, studies have raised the […]
October 15th, 2012
Selections from Richard Lehman’s Literature Review: October 15th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include PCI use in states with public reporting of outcomes; proneurotensin as a prognostic marker for CVD, diabetes, and mortality; vorapaxar for secondary prevention of thrombotic events in patients with previous MI; and atenolol vs. metoprolol for hypertension.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?